A MultIceNTER Phase I Peptide VaCcine Trial to Exploit NeoePitope-Specific T Cells for the Treatment of H3-Mutated Gliomas – (INTERCEPT H3)

2024-514840-97-00 Human pharmacology (Phase I) - Other Ongoing, recruitment ended

Start 15 Feb 2023 · Status Ongoing, recruitment ended · 1 EU/EEA countries · 7 sites

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruitment ended
Participants planned 15
Countries 1
Sites 7

glioma WHO grade IV (C71.1-9 according to ICD-10 classification)

Key facts

Sponsor
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
15 Feb 2023 → ongoing
Decision date (initial)
2024-08-08
Transition trial
Yes
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
Yes

External identifiers

EU CT number
2024-514840-97-00
EudraCT number
2018-002874-40
ClinicalTrials.gov
NCT04808245

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

glioma WHO grade IV (C71.1-9 according to ICD-10 classification)

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts

Sponsor organisation
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts
Address
Im Neuenheimer Feld 280, Neuenheim Neuenheim
City
Heidelberg
Postcode
69120
Country
Germany

Scientific contact point

Organisation
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts
Contact name
Prof. Dr. med. Michael Platten

Public contact point

Organisation
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts
Contact name
Prof. Dr. med. Michael Platten

Locations

1 EU/EEA country · 7 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ongoing, recruitment ended 15 7
Rest of world 0

Investigational sites

Germany

7 sites · Ongoing, recruitment ended
Universitaetsklinikum Essen AöR
Klinische Neuroonkologie, Hufelandstrasse 55, Holsterhausen, Essen
Universitaetsklinikum Bonn AöR
Sektion Klinische Neuroonkologie, Venusberg-Campus 1, Venusberg, Bonn
Universitaetsklinikum Carl Gustav Carus Dresden an der Technischen Universitaet Dresden AöR
Klinik und Poliklinik für Neurochirurgie, Fetscherstrasse 74, Johannstadt-Nord, Dresden
Goethe University Frankfurt
Dr. Senckenbergisches Institut für Neuroonkologie, Theodor-Stern-Kai 7, 60590, Frankfurt Am Main
Universitaetsklinikum Mannheim GmbH
Neurologische Klinik, Theodor-Kutzer-Ufer 1-3, Wohlgelegen, Mannheim
Universitaetsklinikum Heidelberg AöR
Neurologische Klinik, Im Neuenheimer Feld 400, Neuenheim, Heidelberg
Universitaetsklinikum Tuebingen AöR
Neurologie mit Interdisziplinärem Schwerpunkt Neuroonkologie, Hoppe-Seyler-Strasse 3, Nordstadt, Tuebingen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2023-02-15 2023-02-15 2025-08-07

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-07-10 Germany Acceptable with conditions
2024-07-17
2024-08-08
2 SUBSTANTIAL MODIFICATION SM-1 2025-06-18 Germany Acceptable
2025-07-21
2025-07-24
3 NON SUBSTANTIAL MODIFICATION NSM-1 2025-11-17 Germany Acceptable
2025-07-21
2025-11-17
4 NON SUBSTANTIAL MODIFICATION NSM-3 2025-12-03 Germany Acceptable
2025-07-21
2025-12-03